2,313 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by JGP Global Gestao de Recursos Ltda.

Key Points

• JGP Global Gestao de Recursos Ltda. acquired 2,313 shares of Johnson & Johnson for approximately $384,000, making it the firm's 20th largest holding.
• Johnson & Johnson reported quarterly earnings of $2.77 per share, exceeding analysts' expectations of $2.68, with revenue of $23.74 billion, up 5.8% year-over-year.
• The company announced a quarterly dividend of $1.30 per share, with a dividend yield of 3.1%, reflecting a payout ratio of 55.61%.

JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,313 shares of the company's stock, valued at approximately $384,000. Johnson & Johnson comprises 0.3% of JGP Global Gestao de Recursos Ltda.'s investment portfolio, making the stock its 20th largest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Elios Financial Group Inc. increased its position in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after acquiring an additional 66 shares during the last quarter. Atlantic Family Wealth LLC increased its position in shares of Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC increased its position in shares of Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. increased its position in shares of Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after acquiring an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc increased its position in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after acquiring an additional 69 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.6%

Shares of Johnson & Johnson stock opened at $167.33 on Monday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a 50 day moving average of $157.46 and a 200 day moving average of $156.74. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $402.99 billion, a P/E ratio of 17.90, a P/E/G ratio of 2.13 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.1%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Guggenheim reissued a "neutral" rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.